i-Lumen(TM) AMD for Dry Age Related Macular Degeneration

Phase-Based Progress Estimates
Bay Area Retina Associates, Walnut Creek, CA
Dry Age Related Macular Degeneration+4 More
i-Lumen(TM) AMD - Device
All Sexes
What conditions do you have?

Study Summary

Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD).

Eligible Conditions

  • Dry Age Related Macular Degeneration
  • Age - Related Macular Degeneration (AMD)
  • Nonexudative Age Related Macular Degeneration

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Dry Age Related Macular Degeneration

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Through Month 12 timepoint

Through Month 12 timepoint
Mean change best corrected distance visual acuity
Month 12
Adverse Device Effects

Trial Safety

Safety Progress

1 of 3

Other trials for Dry Age Related Macular Degeneration

Trial Design

2 Treatment Groups

i-Lumen AMD Active
1 of 2
i-Lumen AMD Sham
1 of 2
Experimental Treatment
Non-Treatment Group

60 Total Participants · 2 Treatment Groups

Primary Treatment: i-Lumen(TM) AMD · Has Placebo Group · N/A

i-Lumen AMD Active
Experimental Group · 1 Intervention: i-Lumen(TM) AMD · Intervention Types: Device
i-Lumen AMD Sham
ShamComparator Group · 1 Intervention: i-Lumen(TM) AMD Sham · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through month 12 timepoint
Closest Location: Bay Area Retina Associates · Walnut Creek, CA
2008First Recorded Clinical Trial
1 TrialsResearching Dry Age Related Macular Degeneration
31 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.